Clinicaltrialsof16COVIDvaccinesOKd
Admin - admin
于2022年04月23日发表
From: Shenzhen Daily
Updated: 2021-02-22 09:02
China has approved 16 domestically made COVID-19 vaccines for clinical trials, six of which have entered phase III, according to the latest data from the National Medical Products Administration.
Two inactivated COVID-19 vaccines from China have hit the market on a conditional basis: a vaccine from China National Biotec Group affiliated with Sinopharm, and the CoronaVac vaccine developed by Sinovac Biotech. They received their respective approvals from the administration Dec. 30, 2020, and Feb. 5 this year.
In addition to inactivated vaccines, China has adopted four technological approaches to COVID-19 vaccines: recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza viruses as vectors.
As of Feb. 9, China has administered 40.52 million COVID-19 vaccine doses to key groups, said National Health Commission spokesperson Mi Feng at a press conference.
China-developed vaccines have also won global trust.
Foreign Ministry spokesperson Hua Chunying said Friday that at least eight foreign heads of state or government have received Chinese vaccines.
Emphasizing that China’s international cooperation on vaccines aims to make the shots a global public product, Hua said all parties should come together to reject vaccine nationalism, and promote fair and equitable distribution of vaccines, especially in developing countries.
China will continue to develop vaccine cooperation with relevant countries in different ways, and make its own contribution to winning an ultimate victory in defeating the pandemic, Hua added.
Both Mexico and Colombia received their fist batch of Chinese Sinovac vaccines Saturday.
On Saturday, Colombian President Ivan Duque welcomed the arrival of the vaccines, which will be “deployed throughout the national territory.”
The president said that the vaccines will be sent to several remote regions of the country to fight the variant of COVID-19 known as P.1.
